The NDA Advisory Board has appointed Dr Susan Jerian a NCI trained oncologist with experience of leadership in the industry and the FDA.
Dr. Jerian is a NDA expert in drug and biologic development for hematology and oncology indications, combination product development including companion diagnostics, biosimilars, clinical trial design and regulatory strategy with special emphasis on US FDA requirements.
Expansion in the US
The announcement follows on to NDA Group’s expansion in the US in the regions of Princeton, Boston and San Francisco.
“The NDA Advisory Board is one of a kind – no other professional body comes as close to reflecting the current opinions and practices of the world’s regulatory and reimbursement agencies. I am very excited to welcome Dr. Jerian on board. With her experience in and in-depth knowledge of oncology product development as well as her FDA expertise she will be able to add tremendous value to clients in these areas and help them to make new and promising medicines available to patients,” said Dr Werner Van den Eynde, Vice President NDA Advisory Board.